Cure SMA News
cure sma's advocacy efforts have secured newborn screening in almost all 50 states
TIME EQUALS NEURONS for infants diagnosed with SMA. Early diagnosis leads to earlier treatment, preserving neurons and function.
3 FDA-APPROVED TREATMENTS and 20+ in development ARE CHANGING THE LANDSCAPE OF SMA
Cure SMA is beginning to focus on combination therapies that stop progression and increase muscle strength and function.
August 2020 - FDA APPROVES evrysdi
Genentech receives FDA approval of Evrysdi, an oral medication, for spinal muscular atrophy for adult patients and children two+ months.
MAY 2019 - FDA APPROVES ZOLGENSMA
AveXis receives FDA approval of Zolgensma, a gene therapy, for spinal muscular atrophy for patients under two years of age.
DECEMBER 2016 - FDA APPROVES SPINRAZA
Biogen receives FDA approval of Spinraza, making it the first-ever treatment for all patients with spinal muscular atrophy.